The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update

Troy A. Moore, Robert W. Buchanan, Peter F Buckley, John A. Chiles, Robert R. Conley, M. Lynn Crismon, Susan M. Essock, Molly Finnerty, Stephen R. Marder, Del D. Miller, Joseph Patrick McEvoy, Delbert G. Robinson, Nina R. Schooler, Steven P. Shon, T. Scott Stroup, Alexander L. Miller

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent evidence in the pharmacologic treatment of schizophrenia. The goal of the consensus conference was to update and revise the Texas Medication Algorithm Project (TMAP) algorithm for schizophrenia used in the Texas Implementation of Medication Algorithms, a statewide quality assurance program for treatment of major psychiatric illness. Method: Four questions were identified via premeeting teleconferences. (1) Should antipsychotic treatment of first-episode schizophrenia be different from that of multiepisode schizophrenia? (2) In which algorithm stages should first-generation antipsychotics (FGAs) be an option? (3) How many antipsychotic trials should precede a clozapine trial? (4) What is the status of augmentation strategies for clozapine? Subgroups reviewed the evidence in each area and presented their findings at the conference. Results: The algorithm was updated to incorporate the following recommendations. (1) Persons with first-episode schizophrenia typically require lower antipsychotic doses and are more sensitive to side effects such as weight gain and extrapyramidal symptoms (group consensus). Second-generation antipsychotics (SGAs) are preferred for treatment of first-episode schizophrenia (majority opinion). (2) FGAs should be included in algorithm stages after first episode that include SGAs other than clozapine as options (group consensus). (3) The recommended number of trials of other antipsychotics that should precede a clozapine trial is 2, but earlier use of clozapine should be considered in the presence of persistent problems such as suicidality, comorbid violence, and substance abuse (group consensus). (4) Augmentation is reasonable for persons with inadequate response to clozapine, but published results on augmenting agents have not identified replicable positive results (group consensus). Conclusions: These recommendations are meant to provide a framework for clinical decision making, not to replace clinical judgment. As with any algorithm, treatment practices will evolve beyond the recommendations of this consensus conference as new evidence and additional medications become available.

Original languageEnglish (US)
Pages (from-to)1751-1762
Number of pages12
JournalJournal of Clinical Psychiatry
Volume68
Issue number11
DOIs
StatePublished - Jan 1 2007

Fingerprint

Antipsychotic Agents
Clozapine
Schizophrenia
Consensus
Psychiatry
Telecommunications
Therapeutics
Pharmacists
Violence
Weight Gain
Substance-Related Disorders
Mental Health
Public Health

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Moore, T. A., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., ... Miller, A. L. (2007). The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update. Journal of Clinical Psychiatry, 68(11), 1751-1762. https://doi.org/10.4088/JCP.v68n1115

The Texas medication Algorithm project antipsychotic algorithm for schizophrenia : 2006 Update. / Moore, Troy A.; Buchanan, Robert W.; Buckley, Peter F; Chiles, John A.; Conley, Robert R.; Crismon, M. Lynn; Essock, Susan M.; Finnerty, Molly; Marder, Stephen R.; Miller, Del D.; McEvoy, Joseph Patrick; Robinson, Delbert G.; Schooler, Nina R.; Shon, Steven P.; Stroup, T. Scott; Miller, Alexander L.

In: Journal of Clinical Psychiatry, Vol. 68, No. 11, 01.01.2007, p. 1751-1762.

Research output: Contribution to journalArticle

Moore, TA, Buchanan, RW, Buckley, PF, Chiles, JA, Conley, RR, Crismon, ML, Essock, SM, Finnerty, M, Marder, SR, Miller, DD, McEvoy, JP, Robinson, DG, Schooler, NR, Shon, SP, Stroup, TS & Miller, AL 2007, 'The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update', Journal of Clinical Psychiatry, vol. 68, no. 11, pp. 1751-1762. https://doi.org/10.4088/JCP.v68n1115
Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML et al. The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update. Journal of Clinical Psychiatry. 2007 Jan 1;68(11):1751-1762. https://doi.org/10.4088/JCP.v68n1115
Moore, Troy A. ; Buchanan, Robert W. ; Buckley, Peter F ; Chiles, John A. ; Conley, Robert R. ; Crismon, M. Lynn ; Essock, Susan M. ; Finnerty, Molly ; Marder, Stephen R. ; Miller, Del D. ; McEvoy, Joseph Patrick ; Robinson, Delbert G. ; Schooler, Nina R. ; Shon, Steven P. ; Stroup, T. Scott ; Miller, Alexander L. / The Texas medication Algorithm project antipsychotic algorithm for schizophrenia : 2006 Update. In: Journal of Clinical Psychiatry. 2007 ; Vol. 68, No. 11. pp. 1751-1762.
@article{5736d5945a01429e8d05a03492e9dd2c,
title = "The Texas medication Algorithm project antipsychotic algorithm for schizophrenia: 2006 Update",
abstract = "Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent evidence in the pharmacologic treatment of schizophrenia. The goal of the consensus conference was to update and revise the Texas Medication Algorithm Project (TMAP) algorithm for schizophrenia used in the Texas Implementation of Medication Algorithms, a statewide quality assurance program for treatment of major psychiatric illness. Method: Four questions were identified via premeeting teleconferences. (1) Should antipsychotic treatment of first-episode schizophrenia be different from that of multiepisode schizophrenia? (2) In which algorithm stages should first-generation antipsychotics (FGAs) be an option? (3) How many antipsychotic trials should precede a clozapine trial? (4) What is the status of augmentation strategies for clozapine? Subgroups reviewed the evidence in each area and presented their findings at the conference. Results: The algorithm was updated to incorporate the following recommendations. (1) Persons with first-episode schizophrenia typically require lower antipsychotic doses and are more sensitive to side effects such as weight gain and extrapyramidal symptoms (group consensus). Second-generation antipsychotics (SGAs) are preferred for treatment of first-episode schizophrenia (majority opinion). (2) FGAs should be included in algorithm stages after first episode that include SGAs other than clozapine as options (group consensus). (3) The recommended number of trials of other antipsychotics that should precede a clozapine trial is 2, but earlier use of clozapine should be considered in the presence of persistent problems such as suicidality, comorbid violence, and substance abuse (group consensus). (4) Augmentation is reasonable for persons with inadequate response to clozapine, but published results on augmenting agents have not identified replicable positive results (group consensus). Conclusions: These recommendations are meant to provide a framework for clinical decision making, not to replace clinical judgment. As with any algorithm, treatment practices will evolve beyond the recommendations of this consensus conference as new evidence and additional medications become available.",
author = "Moore, {Troy A.} and Buchanan, {Robert W.} and Buckley, {Peter F} and Chiles, {John A.} and Conley, {Robert R.} and Crismon, {M. Lynn} and Essock, {Susan M.} and Molly Finnerty and Marder, {Stephen R.} and Miller, {Del D.} and McEvoy, {Joseph Patrick} and Robinson, {Delbert G.} and Schooler, {Nina R.} and Shon, {Steven P.} and Stroup, {T. Scott} and Miller, {Alexander L.}",
year = "2007",
month = "1",
day = "1",
doi = "10.4088/JCP.v68n1115",
language = "English (US)",
volume = "68",
pages = "1751--1762",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "11",

}

TY - JOUR

T1 - The Texas medication Algorithm project antipsychotic algorithm for schizophrenia

T2 - 2006 Update

AU - Moore, Troy A.

AU - Buchanan, Robert W.

AU - Buckley, Peter F

AU - Chiles, John A.

AU - Conley, Robert R.

AU - Crismon, M. Lynn

AU - Essock, Susan M.

AU - Finnerty, Molly

AU - Marder, Stephen R.

AU - Miller, Del D.

AU - McEvoy, Joseph Patrick

AU - Robinson, Delbert G.

AU - Schooler, Nina R.

AU - Shon, Steven P.

AU - Stroup, T. Scott

AU - Miller, Alexander L.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent evidence in the pharmacologic treatment of schizophrenia. The goal of the consensus conference was to update and revise the Texas Medication Algorithm Project (TMAP) algorithm for schizophrenia used in the Texas Implementation of Medication Algorithms, a statewide quality assurance program for treatment of major psychiatric illness. Method: Four questions were identified via premeeting teleconferences. (1) Should antipsychotic treatment of first-episode schizophrenia be different from that of multiepisode schizophrenia? (2) In which algorithm stages should first-generation antipsychotics (FGAs) be an option? (3) How many antipsychotic trials should precede a clozapine trial? (4) What is the status of augmentation strategies for clozapine? Subgroups reviewed the evidence in each area and presented their findings at the conference. Results: The algorithm was updated to incorporate the following recommendations. (1) Persons with first-episode schizophrenia typically require lower antipsychotic doses and are more sensitive to side effects such as weight gain and extrapyramidal symptoms (group consensus). Second-generation antipsychotics (SGAs) are preferred for treatment of first-episode schizophrenia (majority opinion). (2) FGAs should be included in algorithm stages after first episode that include SGAs other than clozapine as options (group consensus). (3) The recommended number of trials of other antipsychotics that should precede a clozapine trial is 2, but earlier use of clozapine should be considered in the presence of persistent problems such as suicidality, comorbid violence, and substance abuse (group consensus). (4) Augmentation is reasonable for persons with inadequate response to clozapine, but published results on augmenting agents have not identified replicable positive results (group consensus). Conclusions: These recommendations are meant to provide a framework for clinical decision making, not to replace clinical judgment. As with any algorithm, treatment practices will evolve beyond the recommendations of this consensus conference as new evidence and additional medications become available.

AB - Background: A panel of academic psychiatrists and pharmacists, clinicians from the Texas public mental health system, advocates, and consumers met in June 2006 in Dallas, Tex., to review recent evidence in the pharmacologic treatment of schizophrenia. The goal of the consensus conference was to update and revise the Texas Medication Algorithm Project (TMAP) algorithm for schizophrenia used in the Texas Implementation of Medication Algorithms, a statewide quality assurance program for treatment of major psychiatric illness. Method: Four questions were identified via premeeting teleconferences. (1) Should antipsychotic treatment of first-episode schizophrenia be different from that of multiepisode schizophrenia? (2) In which algorithm stages should first-generation antipsychotics (FGAs) be an option? (3) How many antipsychotic trials should precede a clozapine trial? (4) What is the status of augmentation strategies for clozapine? Subgroups reviewed the evidence in each area and presented their findings at the conference. Results: The algorithm was updated to incorporate the following recommendations. (1) Persons with first-episode schizophrenia typically require lower antipsychotic doses and are more sensitive to side effects such as weight gain and extrapyramidal symptoms (group consensus). Second-generation antipsychotics (SGAs) are preferred for treatment of first-episode schizophrenia (majority opinion). (2) FGAs should be included in algorithm stages after first episode that include SGAs other than clozapine as options (group consensus). (3) The recommended number of trials of other antipsychotics that should precede a clozapine trial is 2, but earlier use of clozapine should be considered in the presence of persistent problems such as suicidality, comorbid violence, and substance abuse (group consensus). (4) Augmentation is reasonable for persons with inadequate response to clozapine, but published results on augmenting agents have not identified replicable positive results (group consensus). Conclusions: These recommendations are meant to provide a framework for clinical decision making, not to replace clinical judgment. As with any algorithm, treatment practices will evolve beyond the recommendations of this consensus conference as new evidence and additional medications become available.

UR - http://www.scopus.com/inward/record.url?scp=37049003034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37049003034&partnerID=8YFLogxK

U2 - 10.4088/JCP.v68n1115

DO - 10.4088/JCP.v68n1115

M3 - Article

C2 - 18052569

AN - SCOPUS:37049003034

VL - 68

SP - 1751

EP - 1762

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 11

ER -